Development of antibiotic activity profile screening for the classification and discovery of natural product antibiotics.

Despite recognition of the looming antibiotic crisis by healthcare professionals, the number of new antibiotics reaching the clinic continues to decline sharply. This study aimed to establish an antibiotic profiling strategy using a panel of clinically relevant bacterial strains to create unique biological fingerprints for all major classes of antibiotics. Antibiotic mode of action profile (BioMAP) screening has been shown to effectively cluster antibiotics by structural class based on these fingerprints. Using this approach, we have accurately predicted the presence of known antibiotics in natural product extracts and have discovered a naphthoquinone-based antibiotic from our marine natural product library that possesses a unique carbon skeleton. We have demonstrated that bioactivity fingerprinting is a successful strategy for profiling antibiotic lead compounds and that BioMAP can be applied to the discovery of new natural product antibiotics leads.

[1]  Satoru Miyano,et al.  Open source clustering software , 2004 .

[2]  M. O'Neil-Johnson,et al.  Application of capillary-scale NMR for the structure determination of phytochemicals. , 2005, Phytochemical analysis : PCA.

[3]  Trey Ideker,et al.  Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..

[4]  L. Verbist.  In vitro activity of piperacillin, a new semisynthetic penicillin with an unusually broad spectrum of activity , 1978, Antimicrobial Agents and Chemotherapy.

[5]  A. Cole,et al.  Evolving trends in the dereplication of natural product extracts. 2. The isolation of chrysaibol, an antibiotic peptaibol from a New Zealand sample of the mycoparasitic fungus Sepedonium chrysospermum. , 2008, Journal of natural products.

[6]  Hartmut Laatsch,et al.  Evolving trends in the dereplication of natural product extracts: new methodology for rapid, small-scale investigation of natural product extracts. , 2008, Journal of natural products.

[7]  Jean-Luc Wolfender,et al.  Identification of natural products using HPLC-SPE combined with CapNMR. , 2007, Analytical chemistry.

[8]  Michael A Fischbach,et al.  New antibiotics from bacterial natural products , 2006, Nature Biotechnology.

[9]  G. Carter,et al.  Fumaquinone, a New Prenylated Naphthoquinone from Streptomyces fumanus , 2005, The Journal of Antibiotics.

[10]  J. Collins,et al.  How antibiotics kill bacteria: from targets to networks , 2010, Nature Reviews Microbiology.

[11]  Yiqing Lin,et al.  Microscale LC-MS-NMR platform applied to the identification of active cyanobacterial metabolites. , 2008, Analytical chemistry.

[12]  D. Payne,et al.  Finding the gems using genomic discovery: antibacterial drug discovery strategies – the successes and the challenges , 2004 .

[13]  Christopher T. Walsh,et al.  Antibiotics for Emerging Pathogens , 2009, Science.

[14]  K. Nicolaou,et al.  The Chemistry and Biology of Alkannin, Shikonin, and Related Naphthazarin Natural Products. , 1999, Angewandte Chemie.

[15]  A. Brandelli,et al.  In vitro antimicrobial activity of a new series of 1,4-naphthoquinones. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[16]  C. Walsh.  Opinion — anti-infectives: Where will new antibiotics come from? , 2003, Nature Reviews Microbiology.

[17]  M. Barber,et al.  Penicillinase-resistant Penicillins and Cephalosporins , 1964, British medical journal.

[18]  J. Cate,et al.  Structures of the Escherichia coli ribosome with antibiotics bound near the peptidyl transferase center explain spectra of drug action , 2010, Proceedings of the National Academy of Sciences.

[19]  S. Meshnick,et al.  Molecular Basis for Atovaquone Resistance in Pneumocystis jirovecii Modeled in the Cytochrome bc1Complex of Saccharomyces cerevisiae* , 2004, Journal of Biological Chemistry.

[20]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[21]  Jesús Martín,et al.  Current approaches to exploit actinomycetes as a source of novel natural products , 2011, Journal of Industrial Microbiology & Biotechnology.

[22]  L. Silver.  Challenges of Antibacterial Discovery , 2011, Clinical Microbiology Reviews.

[23]  R. Naginienė,et al.  Antibiotic resistance mechanisms of clinically important bacteria. , 2011, Medicina.

[24]  J. Bartlett,et al.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  K. Hong,et al.  Actinomycetes for Marine Drug Discovery Isolated from Mangrove Soils and Plants in China , 2009, Marine drugs.

[26]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[27]  M. Davies-Coleman,et al.  Cytotoxic and antioxidant marine prenylated quinones and hydroquinones. , 2012, Natural product reports.

[28]  K. Drlica,et al.  DNA gyrase, topoisomerase IV, and the 4-quinolones , 1997, Microbiology and molecular biology reviews : MMBR.

[29]  E. Bishburg,et al.  Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. , 2009, International journal of antimicrobial agents.

[30]  S. Ōmura,et al.  Novel antibiotics, furaquinocins C, D, E, F, G and H. , 1991, The Journal of antibiotics.

[31]  N. Heida,et al.  Lactonamycin, a new antimicrobial antibiotic produced by Streptomyces rishiriensis MJ773-88K4. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. , 1999, The Journal of antibiotics.

[32]  L. Peterson.  Bad bugs, no drugs: no ESCAPE revisited. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Soon-ja Kim,et al.  Antibacterial activity of novel naphthoquiones derivatives , 2009, Genes & Genomics.

[34]  S. Ōmura,et al.  Structures of novel antibiotics, furaquinocins A and B , 1989 .

[35]  K. Shin‐ya,et al.  Isolation and structural elucidation of an antioxidative agent, naphterpin. , 1990, The Journal of antibiotics.

[36]  M. Stasevych,et al.  Synthesis, chemical properties, and antimicrobial activity of 2- and 2,3-substituted [(tetrahydro-2,4-dioxopyrimidin-1(2H)-yl)phenoxy]naphthalene-1,4-diones , 2011 .

[37]  Philippe J. Eugster,et al.  Advanced methods for natural product drug discovery in the field of nutraceuticals. , 2011, Chimia.